## Protocol Section
### Identification Module
**NCT ID:** NCT01055379

**Acronym:** ACCORDO

**Brief Title:** Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn

**Official Title:** A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study

#### Organization Study ID Info
**ID:** 12962A
#### Organization
**Class:** INDUSTRY
**Full Name:** Lundbeck Italia S.p.A.
#### Secondary ID Infos
**ID:** 2009-011144-19
**Type:** EUDRACT_NUMBER
### Status Module
#### Completion Date
**Date:** 2012-07

**Type:** ACTUAL

#### Expanded Access Info
#### Last Update Post Date
**Date:** 2021-08-31

**Type:** ACTUAL

**Last Update Submit Date:** 2021-08-30

**Overall Status:** COMPLETED

#### Primary Completion Date
**Date:** 2012-07

**Type:** ACTUAL

#### Start Date
**Date:** 2010-03

**Status Verified Date:** 2021-08

#### Study First Post Date
**Date:** 2010-01-25
**Type:** ESTIMATED
**Study First Submit Date:** 2010-01-22
**Study First Submit QC Date:** 2010-01-22
### Sponsor Collaborators Module

#### Collaborators

**Class:** INDUSTRY

**Name:** Teva Branded Pharmaceutical Products R&D, Inc.

#### Lead Sponsor

**Class:** INDUSTRY

**Name:** Lundbeck Italia S.p.A.

#### Responsible Party

**Type:** SPONSOR

### Oversight Module

**Oversight Has DMC:** False

### Description Module

**Brief Summary:** The primary endpoint for this study is the clinical response after 12 weeks of treatment, defined as a change in total score from baseline depressive symptoms as measured by the Beck Depression Inventory-Amended (BDI-IA) total score.

**Detailed Description:** ACCORDO is a multicentre, randomised, double-blind, and placebo-controlled study conducted in 12 Italian centres. Subjects are screened by means of the BDI-IA (cut-off 15) and randomised to treatment with rasagiline or placebo for 12 weeks.

Subjects have to be on stable treatment with dopaminergic agents at least 4 weeks before baseline, and maintained so during the course of the study.

The primary objective is to evaluate whether rasagiline compared to placebo improves depressive symptoms as evaluated by the BDI-IA total score.

### Conditions Module

**Conditions:**

- Depressive Symptoms

- Parkinson's Disease

**Keywords:**

- Rasagiline

- Depressive Symptoms

- Cognition

### Design Module

#### Design Info

**Allocation:** RANDOMIZED

**Intervention Model:** PARALLEL

##### Masking Info

**Masking:** DOUBLE

**Who Masked:**

- PARTICIPANT

- INVESTIGATOR

**Primary Purpose:** TREATMENT

#### Enrollment Info

**Count:** 121

**Type:** ACTUAL

**Phases:**

- PHASE4

**Study Type:** INTERVENTIONAL

### Arms Interventions Module

#### Arm Group 1

**Intervention Names:**

- Drug: Rasagiline

**Label:** Rasagiline

**Type:** EXPERIMENTAL

#### Arm Group 2

**Intervention Names:**

- Drug: Placebo

**Label:** Placebo

**Type:** PLACEBO_COMPARATOR

### Interventions

#### Intervention 1

**Arm Group Labels:**

- Rasagiline

**Description:** 1 mg/day for 12 weeks; orally

**Name:** Rasagiline

**Other Names:**

- Azilect

**Type:** DRUG

#### Intervention 2

**Arm Group Labels:**

- Placebo

**Description:** Once daily for 12 weeks; orally

**Name:** Placebo

**Type:** DRUG

### Outcomes Module

#### Primary Outcomes

**Measure:** Change from baseline in BDI-IA total score

**Time Frame:** 12 weeks

#### Secondary Outcomes

**Measure:** Evaluate if rasagiline compared to placebo improves cognitive function, over a treatment period of 12 weeks in idiopathic Parkinson´s Disease, using a formal neuropsychiatric cognitive test battery; quality of life (PDQ 39); apathy; ADL, motor function

**Time Frame:** 12 weeks

**Measure:** Change in quality of life using the PDQ-39 scale

**Time Frame:** 12 weeks

**Measure:** Change in apathy using the Apathy Scale

**Time Frame:** 12 weeks

**Measure:** Change in ADL and motor function using UPDRS scales part II and III, respectively

**Time Frame:** 12 weeks

### Eligibility Module

**Eligibility Criteria:** Inclusion Criteria:

* Outpatient, male or female aged \>=40 and \<80 years. The subject has a diagnosis of idiopathic Parkinson's Disease (PD) according to the United Kingdom Parkinson's Disease Society brain bank diagnostic criteria for PD for the clinical diagnosis of PD.
* Depressive symptoms with a minimum severity of \>=15 using the BDI-IA.
* Hoehn and Yahr stage I-III.
* Under stable (4 weeks prior to baseline) dopaminergic treatment without significant motor complication such as "on-off" phenomena and/or dyskinesia.
* The subject and/or legal representative and/or impartial witness is/are able to read and understand the Subject Information Sheet.
* The subject and/or legal representative has/have signed the Informed Consent Form (ICF) and if relevant the impartial witness has co-signed the ICF.
* If female, must: agree not to try to become pregnant during the study (female patients of childbearing potential will take pregnancy test, using a urine stick), AND use adequate contraception (adequate contraception is defined as oral/systemic contraception, intrauterine device, diaphragm in combination with spermicidal, or condom for male partner in combination with spermicidal), OR have been menopausal for at least 24 months prior to baseline, (OR) have been surgically sterilised prior to baseline, OR have had a hysterectomy prior to baseline.

Exclusion Criteria:

A subject, who meets one or more of the following criteria at the Baseline Visit, is not eligible for inclusion in this study:

* Motor complications such as wearing off and on-off phenomena.
* Mini-Mental State Examination (MMSE) \<26, corrected score.
* Diagnosis of current or history of major depressive episode according to DSM-IV-TR® criteria within 1 year before recruitment into the study.
* Presence of any other neurodegenerative disorder other than PD, based on judgement of investigator.
* Psychotic symptoms, e.g. hallucination and delirium (determined by clinical evaluation).
* Presence of any unstable or untreated systemic disorder such as diabetes, cardiac failure, or renal failure.
* Use of any prohibited concomitant medication according to the timelines provided in Appendix II.
* Patient who have undergone Deep Brain Stimulation surgery.
* Current treatment with antidepressants or history of treatment with antidepressants less than 1 month prior to randomisation.
* Current treatment or history of treatment less than 1 month prior to randomisation, with antipsychotics, cholinesterase inhibitors, memantine, amantadine, or anticholinergics.
* Current treatment with selegiline or history of treatment with selegiline less than 90 days prior to randomisation.

**Maximum Age:** 80 Years

**Minimum Age:** 40 Years

**Sex:** ALL

**Standard Ages:**

- ADULT

- OLDER_ADULT

### Contacts Locations Module

#### Locations

**Location 1:**

**City:** Cagliari

**Country:** Italy

**Facility:** IT010

**Zip:** 9134

**Location 2:**

**City:** Chieti

**Country:** Italy

**Facility:** IT007

**Zip:** 66013

**Location 3:**

**City:** Genova

**Country:** Italy

**Facility:** IT004

**Zip:** 16132

**Location 4:**

**City:** Lido di Camaiore

**Country:** Italy

**Facility:** IT005

**Zip:** 55043

**Location 5:**

**City:** Messina

**Country:** Italy

**Facility:** IT003

**Zip:** 98122

**Location 6:**

**City:** Milano

**Country:** Italy

**Facility:** IT012

**Zip:** 20135

**Location 7:**

**City:** Naples

**Country:** Italy

**Facility:** IT001

**Zip:** 80131

**Location 8:**

**City:** Roma

**Country:** Italy

**Facility:** IT011

**Zip:** 161

**Location 9:**

**City:** Rome

**Country:** Italy

**Facility:** IT008

**Zip:** 133

**Location 10:**

**City:** Torino

**Country:** Italy

**Facility:** IT015

**Zip:** 10126

**Location 11:**

**City:** Venezia

**Country:** Italy

**Facility:** IT013

**Zip:** 30126

**Location 12:**

**City:** Verona

**Country:** Italy

**Facility:** IT009

**Zip:** 37134

#### Overall Officials

**Official 1:**

**Affiliation:** LundbeckClinicalTrials@lundbeck.com

**Name:** Email contact via H. Lundbeck A/S

**Role:** STUDY_DIRECTOR

### References Module

#### Available IPDs

**ID:** 2009-011144-19

**Type:** EMA EudraCT Results

**URL:** https://www.clinicaltrialsregister.eu/ctr-search/trial/2009-011144-19/results

## Derived Section

### Condition Browse Module - Ancestors

- ID: D000020734

- Term: Parkinsonian Disorders

- ID: D000001480

- Term: Basal Ganglia Diseases

- ID: D000001927

- Term: Brain Diseases

- ID: D000002493

- Term: Central Nervous System Diseases

- ID: D000009422

- Term: Nervous System Diseases

- ID: D000009069

- Term: Movement Disorders

- ID: D000080874

- Term: Synucleinopathies

- ID: D000019636

- Term: Neurodegenerative Diseases

- ID: D000001526

- Term: Behavioral Symptoms

### Condition Browse Module - Browse Branches

- Abbrev: BXM

- Name: Behaviors and Mental Disorders

- Abbrev: All

- Name: All Conditions

- Abbrev: BC10

- Name: Nervous System Diseases

- Abbrev: BC04

- Name: Neoplasms

- Abbrev: BC17

- Name: Skin and Connective Tissue Diseases

- Abbrev: BC18

- Name: Nutritional and Metabolic Diseases

### Condition Browse Module - Browse Leaves

- ID: M29705

- Name: Cognitive Dysfunction

- Relevance: LOW

- As Found: Unknown

- ID: M7058

- Name: Depression

- Relevance: HIGH

- As Found: Depressive Symptoms

- ID: M7061

- Name: Depressive Disorder

- Relevance: LOW

- As Found: Unknown

- ID: M13213

- Name: Parkinson Disease

- Relevance: HIGH

- As Found: Parkinson's Disease

- ID: M22494

- Name: Parkinsonian Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M25603

- Name: Ganglion Cysts

- Relevance: LOW

- As Found: Unknown

- ID: M16358

- Name: Synovial Cyst

- Relevance: LOW

- As Found: Unknown

- ID: M4774

- Name: Basal Ganglia Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M5204

- Name: Brain Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M5742

- Name: Central Nervous System Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M12029

- Name: Movement Disorders

- Relevance: LOW

- As Found: Unknown

- ID: M2217

- Name: Synucleinopathies

- Relevance: LOW

- As Found: Unknown

- ID: M21558

- Name: Neurodegenerative Diseases

- Relevance: LOW

- As Found: Unknown

- ID: M4818

- Name: Behavioral Symptoms

- Relevance: LOW

- As Found: Unknown

### Condition Browse Module - Meshes

- ID: D000010300

- Term: Parkinson Disease

- ID: D000003863

- Term: Depression

### Intervention Browse Module - Ancestors

- ID: D000008996

- Term: Monoamine Oxidase Inhibitors

- ID: D000004791

- Term: Enzyme Inhibitors

- ID: D000045504

- Term: Molecular Mechanisms of Pharmacological Action

- ID: D000018696

- Term: Neuroprotective Agents

- ID: D000020011

- Term: Protective Agents

- ID: D000045505

- Term: Physiological Effects of Drugs

### Intervention Browse Module - Browse Branches

- Abbrev: NeuroAg

- Name: Neuroprotective Agents

- Abbrev: All

- Name: All Drugs and Chemicals

### Intervention Browse Module - Browse Leaves

- ID: M213846

- Name: Rasagiline

- Relevance: HIGH

- As Found: Sudden

- ID: M11960

- Name: Monoamine Oxidase Inhibitors

- Relevance: LOW

- As Found: Unknown

- ID: M7951

- Name: Enzyme Inhibitors

- Relevance: LOW

- As Found: Unknown

- ID: M20773

- Name: Neuroprotective Agents

- Relevance: LOW

- As Found: Unknown

- ID: M21869

- Name: Protective Agents

- Relevance: LOW

- As Found: Unknown

### Intervention Browse Module - Meshes

- ID: C000031967

- Term: Rasagiline

### Misc Info Module

- Version Holder: 2024-05-24
